Find generic entry opportunities
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Anticipate generic drug launch
Drug patents …
… from Kazakhstan to Kalamazoo
Proactively manage your pharmacy inventory
Manage your formulary budget
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Method of enhancing paramagnetism in chelates for MRI|
|Abstract:||A diagnostic medium contains at least one physiologically well tolerated complex salt comprising an anion of a complexing acid and one or more central ion or ions of an element with an atomic number of 21 to 29, 42, 44 or 57 to 83 and, optionally, one or more physiologically biocompatible cation or cations of an inorganic and/or organic base or amino acid, optionally, with additives customary in galenic formulations, dissolved or suspended in an aqueous medium.|
|Inventor(s):||Gries; Heinz (Berlin, DE), Rosenberg; Douwe (Berlin, DE), Weinmann; Hanns-Joachim (Berlin, DE), Speck; Ulrich (Berlin, DE), Mutzel; Wolfgang (Berlin, DE), Hoyer; Georg-Alexander (Berlin, DE), Pfeiffer; Heinrich (Berlin, DE), Renneke; Franz-Josef (Berlin, DE)|
|Assignee:||Schering Aktiengesellschaft (Berlin, DE)|
Patent Claim Types:|
see list of patent claims
|Use; Composition; Dosage form; Formulation;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Austria||18719||<disabled in preview>|
|Austria||397465||<disabled in preview>|
|Austria||52247||<disabled in preview>|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.